•
Dec 31, 2020

Zimmer Biomet Q4 2020 Earnings Report

Zimmer Biomet's Q4 2020 financial results were announced, revealing a slight decrease in net sales but a strong core business performance amidst COVID-19 pressures.

Key Takeaways

Zimmer Biomet reported Q4 net sales of $2.085 billion, a decrease of 1.9% compared to the prior year. Diluted earnings per share were $1.59, while adjusted diluted earnings per share were $2.11. The company also announced its intention to spin off its Spine and Dental businesses.

Fourth quarter net sales decreased by 1.9%, or 3.7% on a constant currency basis, reaching $2.085 billion.

Diluted earnings per share for the fourth quarter were $1.59, while adjusted diluted earnings per share amounted to $2.11.

Full-year net sales totaled $7.025 billion, representing a decrease of 12.0%, or 12.4% on a constant currency basis.

The company announced plans to spin off its Spine and Dental businesses to form a new, independent publicly traded company.

Total Revenue
$2.09B
Previous year: $2.13B
-1.9%
EPS
$2.11
Previous year: $2.3
-8.3%
Gross Profit
$1.44B
Previous year: $1.54B
-6.8%
Cash and Equivalents
$802M
Previous year: $618M
+29.8%
Free Cash Flow
$329M
Previous year: $295M
+11.3%
Total Assets
$24.4B
Previous year: $24.6B
-0.9%

Zimmer Biomet

Zimmer Biomet

Zimmer Biomet Revenue by Segment

Zimmer Biomet Revenue by Geographic Location

Forward Guidance

Due to the uncertainty surrounding the ongoing impact of COVID-19, the Company is currently unable to quantify the expected impact on its results of operations, financial condition and cash flows for full year 2021 and is not providing financial guidance at this time.

Revenue & Expenses

Visualization of income flow from segment revenue to net income